

Alemtuzumab for treating highly active relapsing remitting multiple sclerosis

Information for the public

Published: 1 May 2014

Last updated: 17 March 2020

www.nice.org.uk

Alemtuzumab (Lemtrada) is available on the NHS as a possible treatment for highly active relapsing–remitting multiple sclerosis in adults who have:

- highly active disease despite a full and adequate course of treatment with at least 1 disease-modifying therapy or
- rapidly-evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year, and with 1 or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load compared with a previous MRI.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Multiple Sclerosis Society](#), 0808 800 8000
- [Multiple Sclerosis Trust](#), 01462 476700

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-0571-3

Accreditation

